Advances in optogenetics for biomedical research

doi:10.12211/2096-8280.2022-030

Synthetic Biology Journal ›› 2023, Vol. 4 ›› Issue (1): 102-140.DOI: 10.12211/2096-8280.2022-030

• Invited Review • Previous Articles Next Articles

Advances in optogenetics for biomedical research

Yuanhuan YU, Yang ZHOU, Xinyi WANG, Deqiang KONG, Haifeng YE

Synthetic Biology and Biomedical Engineering Laboratory，Biomedical Synthetic Biology Research Center，Shanghai Key Laboratory of Regulatory Biology，Institute of Biomedical Sciences and School of Life Sciences，East China Normal University，Shanghai 200241，China

Received:2022-05-26 Revised:2022-09-05 Online:2023-03-07 Published:2023-02-28
Contact: Haifeng YE

光遗传学照进生物医学研究进展

于袁欢, 周阳, 王欣怡, 孔德强, 叶海峰

华东师范大学生命科学学院，上海市调控生物学重点实验室，华东师范大学医学合成生物学研究中心，上海　200241

通讯作者: 叶海峰
作者简介:于袁欢（1992—），女，博士。研究方向为合成生物学与生物医学工程。
周阳（1994—），男，博士研究生。研究方向为合成生物学与生物医学工程。
于袁欢（1992—），女，博士。研究方向为合成生物学与生物医学工程。E-mail：yuyuanhuan@admin.ecnu.edu.cn
周阳（1994—），男，博士研究生。研究方向为合成生物学与生物医学工程。
周阳（1994—），男，博士研究生。研究方向为合成生物学与生物医学工程。E-mail：52191300036@stu.ecnu.edu.cn
叶海峰（1981—），男，研究员，博士生导师。主要从事合成生物学与生物医学工程领域的研究。利用合成生物学的理念和方法对细胞进行遗传学改造和重编程，重新设计、构建智能基因网络调控系统用于疾病的精准治疗。研究内容包括：遗传控制系统设计构建、智能细胞药物设计构建、光遗传学工具开发、精准可控的肿瘤免疫治疗、药物工程菌设计改造等。E-mail：hfye@bio.ecnu.edu.cn
基金资助:
国家重点研发计划(2019YFA0904500);国家自然科学基金(31971346);上海市科委(22N31900300)

Abstract

Abstract:

Synthetic biology enables rational design of regulatory molecules and circuits to reprogram cellular behaviors, and its applications to human cells could lead to powerful gene- and cell-based therapies, which are well recognized as central pillars of next-generation medicines. However, the safety of these therapies remains to be assessed, and controllability is a critical issue affecting their safety and limiting their clinical applications. In recent years, optogenetic technologies have been widely used in biomedical applications, which provides new insights for treating intractable diseases due to their distinguishing features of non-invasiveness, reversibility, and spatiotemporal resolution. Light is an ideal inducer to control gene expression, enabling precise and spatiotemporal manipulation of gene expression and cell behaviors by illuminating with light of appropriate intensity and wavelength as a triggering signal to achieve pinpoint spatiotemporal control of cellular activities. With the development of optogenetic toolkits, optogenetics has recently been developed for therapeutic applications. In this review, we summarize various optogenetic tools responsive to different wavelengths and their applications for precise treatment of neurological diseases, tumors, cardiovascular diseases, diabetes, enteric diseases as well as for the optogenetic control of gene transcription, gene editing, gene recombination and organelle movement. At the same time, we introduce recent research progress in portable bioelectronic medicine and artificial intelligence-assisted diagnosis and treatment systems, which are based on optogenetic techniques and the intelligent electronic devices. The rapid development of optogenetics has enormously extended the scope of traditional bioelectronic medicine, and the remote-controllability, reversibility, and negligible toxicity of optical control systems provide a solid foundation for the application of optogenetics in biomedicine. The success of these approaches would have an impact on precision medicine in the future practice. Finally, we also discuss the shortcomings of existing optogenetic tools and the challenges that would be faced in the future clinical applications as well as the prospects of their development. {L-End}

Key words: synthetic biology, optogenetics, light-controlled gene switch, gene therapy, cell therapy

摘要：

近年来，光遗传学技术因具有非侵入性、可逆性、时空特异性等优点被广泛应用于生物医学研究领域，为疾病治疗提供了新思路和新理念。光作为一种理想的基因表达诱导物，以前所未有的时空精度操控基因表达和细胞行为。随着光遗传学技术的深入研究，基于光遗传学的个性化精准治疗和临床转化成为可能。本文主要介绍了响应不同波长的光遗传学工具及其用于神经系统疾病、肿瘤、心血管疾病、糖尿病、肠道疾病等精准治疗和用于控制基因转录表达、基因编辑、基因重组以及细胞器运动等应用。同时也介绍了光遗传学技术与智能电子设备的有机结合及其在便携式生物电子药物、人工智能诊疗方面的最新研究进展。光遗传学的迅速发展极大地拓展了传统生物电子医学领域。光控系统的远程可控性、可逆性和无毒性为光遗传学在生物医学中的应用提供了坚实的基础。这些方法的成功将对未来实践中的精准医疗产生持久的影响。最后探讨了光遗传学工具存在的问题和在未来临床应用面临的挑战，并对其未来发展前景进行了展望。

关键词: 合成生物学, 光遗传学, 光控基因开关, 基因治疗, 细胞治疗

CLC Number:

Yuanhuan YU, Yang ZHOU, Xinyi WANG, Deqiang KONG, Haifeng YE. Advances in optogenetics for biomedical research[J]. Synthetic Biology Journal, 2023, 4(1): 102-140.

于袁欢, 周阳, 王欣怡, 孔德强, 叶海峰. 光遗传学照进生物医学研究进展[J]. 合成生物学, 2023, 4(1): 102-140.

Figures/Tables 16

Table 1 Characteristics of photosensitive proteins commonly used in mammalian cells

光响应元件	发光基团	光响应机理	来源	活化与失活光照条件/nm	结合与解离半衰期	典型应用	参考文献
UVR8	—	解聚	Arabidopsis thaliana	300/黑暗	ms/h	控制趋化因子释放	[38]
UVR8-COP1	—	异源二聚	Arabidopsis thaliana	300/黑暗	ms/h	转基因表达	[39]
PhoCI	—	光裂解	Clavularia	380/—	min/—	控制蛋白质的清除	[40-41]
ChR2	Retinal	离子通道	Chlamydomonas reinhardtii	450/—	0.2 ms/15 ms	帕金森综合征等神经退行性疾病	[1, 42-43]
Melanopsin	Retinal	离子通道	Mammalian retina	450/—	ms/s	糖尿病血糖控制	[7]
LOV	FMN	结构变异	Avena sativa	450/黑暗	10 s/50 s	钙离子信号控制、基因重组	[44-45]
AsLOV-Zdk1	FMN	解聚	Avena sativa	450/黑暗	s/30～50 s	Notch信号控制、血糖控制	[46-47]
cpLOV-Zdk2	FMN	解聚	Avena sativa	450/黑暗	s/30～50 s	转录调控、细胞死亡	[48]
VVD	FMN/FAD	同源二聚	Neurospora crassa	450/黑暗	s/h	控制RNA功能和代谢、基因重组、细胞消融	[8-49]
CRY2	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	细胞坏死	[50-51]
CRY2clust	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	钙信号控制	[52]
CRY2olig	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	细胞通讯、钙信号控制	[53]
CRY2-CIB1	FAD	异源二聚	Arabidopsis thaliana	450/黑暗	10 s/12 min	表观遗传控制、转录调控、基因重组、RNA修饰	[54]
nMag-pMag	FMN	异源二聚	Neurospora crassa	450/黑暗	1.5 s/6.8 s	转录调控、基因重组	[49]
EL222	FMN	同源二聚	Erythrobacter litoralis	450/黑暗	s/s	转录调控细胞迁移、细胞死亡	[55]
TtCBD	AdoCbl, MetCbl or CNCbl	解聚	Thermus thermophilus	545/黑暗	—	细胞迁移、转基因表达	[56-59]
Dronpa	—	解聚	Pectiniidae	500/400	s/s	控制Raf-MEK-ERK信号	[60-63]
PhyB-PIF3/PIF6	PCB	异源二聚	Arabidopsis thaliana	660/740	1.3 s/4 s	T细胞激活、转基因表达、基因重组	[64- 65]
BphS	BV	催化产生c-di-GMP	Rhodobacter sphaeroides	680～810/—	15 s/90 s	转基因表达、糖尿病血糖控制	[13-14, 18, 66-67]
BphP1-PpsR2	BV	异源二聚	Rhodopseudomonas palustris	760/640	30 s/15 min	转基因表达	[68-69]
PhyA-FHY1/FHL	PCB	异源二聚	Arabidopsis thaliana	660/740	—	转基因表达、转录调控	[70-71]

Table 1 Characteristics of photosensitive proteins commonly used in mammalian cells

光响应元件	发光基团	光响应机理	来源	活化与失活光照条件/nm	结合与解离半衰期	典型应用	参考文献
UVR8	—	解聚	Arabidopsis thaliana	300/黑暗	ms/h	控制趋化因子释放	[38]
UVR8-COP1	—	异源二聚	Arabidopsis thaliana	300/黑暗	ms/h	转基因表达	[39]
PhoCI	—	光裂解	Clavularia	380/—	min/—	控制蛋白质的清除	[40-41]
ChR2	Retinal	离子通道	Chlamydomonas reinhardtii	450/—	0.2 ms/15 ms	帕金森综合征等神经退行性疾病	[1, 42-43]
Melanopsin	Retinal	离子通道	Mammalian retina	450/—	ms/s	糖尿病血糖控制	[7]
LOV	FMN	结构变异	Avena sativa	450/黑暗	10 s/50 s	钙离子信号控制、基因重组	[44-45]
AsLOV-Zdk1	FMN	解聚	Avena sativa	450/黑暗	s/30～50 s	Notch信号控制、血糖控制	[46-47]
cpLOV-Zdk2	FMN	解聚	Avena sativa	450/黑暗	s/30～50 s	转录调控、细胞死亡	[48]
VVD	FMN/FAD	同源二聚	Neurospora crassa	450/黑暗	s/h	控制RNA功能和代谢、基因重组、细胞消融	[8-49]
CRY2	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	细胞坏死	[50-51]
CRY2clust	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	钙信号控制	[52]
CRY2olig	FAD	同源二聚	Arabidopsis thaliana	450/黑暗	s/min	细胞通讯、钙信号控制	[53]
CRY2-CIB1	FAD	异源二聚	Arabidopsis thaliana	450/黑暗	10 s/12 min	表观遗传控制、转录调控、基因重组、RNA修饰	[54]
nMag-pMag	FMN	异源二聚	Neurospora crassa	450/黑暗	1.5 s/6.8 s	转录调控、基因重组	[49]
EL222	FMN	同源二聚	Erythrobacter litoralis	450/黑暗	s/s	转录调控细胞迁移、细胞死亡	[55]
TtCBD	AdoCbl, MetCbl or CNCbl	解聚	Thermus thermophilus	545/黑暗	—	细胞迁移、转基因表达	[56-59]
Dronpa	—	解聚	Pectiniidae	500/400	s/s	控制Raf-MEK-ERK信号	[60-63]
PhyB-PIF3/PIF6	PCB	异源二聚	Arabidopsis thaliana	660/740	1.3 s/4 s	T细胞激活、转基因表达、基因重组	[64- 65]
BphS	BV	催化产生c-di-GMP	Rhodobacter sphaeroides	680～810/—	15 s/90 s	转基因表达、糖尿病血糖控制	[13-14, 18, 66-67]
BphP1-PpsR2	BV	异源二聚	Rhodopseudomonas palustris	760/640	30 s/15 min	转基因表达	[68-69]
PhyA-FHY1/FHL	PCB	异源二聚	Arabidopsis thaliana	660/740	—	转基因表达、转录调控	[70-71]

Fig. 1 Schematic diagram for the optogenetic tools responsive to ultraviolet and violet light(a) In the presence of UV light, homodimerized UVR8 dissociates into monomers and its fused proteins also depolymerizes. (b) Homodimerized UVR8 cannot bind to its ligand COP1 under dark conditions, but UVR8 binds to COP1 to form a heterodimer upon UV light illumination. (c) Violet light induces irreversible self-photocleavage of PhoC1 resulting in the quenching of green fluorescence.POI—protein of interest

Fig. 2 Schematic diagram for the optogenetic tools responsive to blue light(a) The blue light-responsive cation channel protein ChR2 is activated to induce influx of Ca2+ and Na+ by blue light illumination. (b) Under blue light illumination conditions, the chromophore retinal is isomerized to lead to the conformational changes of melanopsin thereby activating phospholipase C (PLC) through G protein (Gαq) and phospholipase C (PLC), which triggers Ca2+ influx by activating transient receptor potential ion channels (TRPCs) on the cell membrane and from the endoplasmic reticulum (ER). (c) With blue light illumination, a light-induced conformation is developed between the AsLOV protein core and the flavoprotein FMN, which results in undocking and unwinding of the LOV2 C-terminal Jα helix. (d) With blue light illumination, a light-induced conformation is formed between the cpLOV and the flavoprotein FMN, which leads to undocking and unwinding of the LOV2 C-terminal Jα helix. (e) Blue light induces the homodimerization of VVD, thus enabling proximity of the fused proteins. (f) Blue light induces the heterodimerization of pMag and nMag, thus enabling proximity of the fused target protein (g) LOVTRAP is a blue light responsive protein dissociation system, which is a reversible light-induced protein system. Zdk1 binds to LOV domain to form a heterodimer under dark conditions, but dissociates from LOV domain upon blue light illumination. (h) Under dark conditions, the N-terminal LOV photoreceptive domain of the light-sensitive protein EL222 binds to its C-terminal HTH DNA-binding domain, thus preventing EL222 dimerization and DNA binding, while blue light irradiation enables EL222 dimerization to recognize its target DNA sequences. (i) Blue light triggers heterodimerization of CRY2 and CIB1 to initiate gene expression. (j) Blue light triggers oligomerization of CRY2, while CRY2 forms a monomer under dark conditions. (k) Blue light triggers multimerization of CRY2clust/olig.

Fig. 3 Schematic diagram for the optogenetic tools responsive to cyan and yellow light(a) The fluorescent proteins Dronpa145N and Dronpa145K dimerizes under dark conditions, while the Dronpa protein undergoes a conformational change that enables depolymerization into monomers in the presence of cyan light. (b) Under dark conditions, pdDronpa homodimerizes and thus blocks the active sites of target proteins, while blue light illumination causes dissociation of the homodimers to expose the active sites of target proteins. (c) Cyan light illumination causes dissociation of the homotetramerized TtCBD. (d) Synthetic light-gated GPCRs (Opto-XRs) undergoes a conformational change that enables the activation of G-protein-mediated intracellular signaling cascades by cyan light illumination. (e) Yellow light-mediated activation of NpHR which triggers Cl- infux.

Fig. 4 Schematic diagram for the optogenetic tools responsive to red/far red light(a) Phytochrome B (PhyB) maintains at Pr form which is biologically inactive in the dark. Red light illumination converts PhyB into the Pfr form and induces heterodimerization with PIF6 in the presence of the photosensitive pigment PCB. (b) In the dark, truncated Phytochrome A (ΔPhyA) maintains at Pr form, red light illumination converts ΔPhyA into the Pfr form and induces heterodimerization with FHY1 in the presence of the photosensitive pigment PCB. (c) Red light induces dissociation of homodimerized BphP1 which can interact with PpsR2 to form a heterodimerization pair.

Fig. 5 Development and application of optogenetic tools in neurobiology(a) Three major types of opsins used in neurobiology. The blue light-responsive cation channel protein ChR2 is activated to induce influx of Ca2+ and Na+ and trigger an action potential. The yellow light-responsive NpHR is activated to allow chloride ions to enter the cytoplasm. Synthetic light-gated GPCRs (Opto-XRs) is engineered by replacing the intracellular domain of rhodopsin with that of G protein-coupled receptors to enable G-protein mediated intracellular signaling cascades. (b) Genetic targeting of ChR2 into the amygdala region of mouse brain enables optical control of the neural pathway of the mouse-hunting behavior by implanting optical fibers. (c) Genetic targeting of ChR2/NpHR into the cervical dorsal spinal cord of mice enables specific activation or suppression of the neurons, and avoids stimulation of non-targeted cells. (d) ChR2 is delivered into the deep brain neurons of mice by coupling with lanthanide-doped upconversion nanoparticles (UCNP), which can convert blue light to tissue-penetrable NIR light to activate ChR2 expressed dopaminergic neurons.

Fig. 6 Optogenetic tools used for tumor therapy(a) Photochemokine receptors used for immunotherapy in murine melanoma. Under 505 nm light illumination, the chimeric photoactivated chemokine receptor composed of rhodopsin α subunit and chemokine receptor-4 (CXCR4) is activated to induce T cell polarization, resulting in the inhibition of tumor growth. (b) Opto-CRAC for cellular immunotherapy. Under blue light illumination, the Jα helix at the carboxyl terminus of LOV2 domain dislocates to expose the C-terminus of STIM1 protein, which stimulates the ORAI1 Ca2+ channel to initiate the calcium-dependent cascade and

Fig. 7 Applications of optogenetic tools in treating cardiovascular diseases(a) Cyanobacterial photosynthetic systems for myocardial ischemia treatment. The cyanobacteria are injected into the hearts of the acute myocardial infarction model rats to produce oxygen through photosynthesis under light illumination conditions, which increases the metabolic activity of cardiomyocytes to improve ventricular function and alleviate acute tissue ischemia. (b) Optogenetic pacemakers. The non-selective cation channel ChR2 is used to control the cardiac excitability. (c) Inhibitory photosensitive protein systems for cardiovascular diseases treatment. ARCH-T mediated H+ efflux can inhibit myocardial activity and alleviate arrhythmia under yellow light illumination. (d) Optogenetic pacemakers for modulating cardiomyocyte activity. Melanopsin, a photoactivated G-protein-coupled receptor, activates the phospholipase C and catalyzes the hydrolysis of PIP2 to produce IP3, enabling release of Ca2+ and enhancement of the pacing activity of cardiomyocytes under blue light (470 nm) illumination conditions.

Fig. 8 Optogenetic tools for diabetes therapy(a) Melanopsin-based blue light regulatory systems for diabetes treatment. Upon blue light stimulation, the melanopsin conformation is changed, thereby activating phospholipase C (PLC) through G protein (Gαq) and phospholipase C (PLC), which triggers Ca2+ influx by the activation of transient receptor potential ion channels (TRPCs) on the cell membrane and from the endoplasmic reticulum (ER). The activated NFAT translocates into the nucleus, and binds to its specific promoter (PNFAT), which initiates the GLP-1 gene expression to control blood glucose homeostasis. (b) The light-oxygen-voltage domain-based blue light regulatory system for diabetes treatment. In the presence of substrate, blue light is produced by the luciferase-catalyzed reaction, leading to the dimerization of the photosensitive protein Vivid. The DNA binding domain Gal4 (1-65 aa) fuses with Vivid and VP16 for incorporation into the nucleus to bind to the DNA operator (5 × UAS), which initiates the expression of insulin to control blood glucose homeostasis. (c) ΔPhyA-based red light regulatory systems for diabetes treatment. Under red light illumination, the hybrid transactivator FHY1-VP64 can be translocated into nucleus by photosensitive DNA binding elements (ΔPhyA-Gal4), in which it can bind to a particular operon sequence (5×UAS) to initiate the expression of insulin. The microcapsules containing engineered cells are implanted into the back of diabetic mice, through which the cells can be induced to produce insulin to control blood glucose homeostasis under red light illumination conditions.

Fig. 9 Light-controlled DNA recombination based on split-Cre recombinase(a) Photoactivatable Cre recombinase systems based on Cry2-CIBN. Under dark conditions, Cre recombinase is dissociated into two inactive parts. Under blue light illumination, CRY2 undergoes a conformational change and binds to CIBN, which induces CreC and CreN to form a complete Cre recombinase for restoration of its activity. (b) Photo-controlled Cre recombinase systems based on Magnet (pMag and nMag). Blue light illumination enables the dimerization of pMag and nMag to reconstitute a complete Cre recombinase to permit light-dependent DNA recombination. (c) A far-red light-inducible split Cre-loxP (FISC) system. Under far-red light illumination, the photosensitive protein BphS converts GTP into c-di-GMP within cells, which triggers the dimerization of BldD to fuse with transcriptional activator p65-VP64 for translocation into the nucleus to initiate the expression of DocS-CreC. Constitutive expressed CreN-Coh2 is driven by the CMV promoter. The catalytic activities of Cre recombinase can be restored through affinity interactions of their respective Coh2 and DocS fusion domains.

Fig. 10 Light-controlled gene editing systems based on CRISPR-Cas9(a) Photoactivatable CRISPR-Cas9 systems based on pMag-nMag. Under dark conditions, Cas9 is splitted into two fragments without nuclease activity. With blue light illumination, the NCas9 and CCas9 domains can be reassociated to form a complete Cas9 by the light-dependent dimerization of pMag and nMag, thereby reconstituting editing for targeted genes. (b) Photoactivatable CRISPR-Cas9 systems based on protected sgRNA. Under dark conditions, the seed sequence of sgRNA is bound by an oligonucleotide that could be cleaved by UV light. With UV light illumination, the oligonucleotide is broken, and the seed sequence of sgRNA is exposed to allow Cas9 to bind to and cleave the target DNA. (c) Near-infrared light-regulated CRISPR-Cas9 systems based on UCNPs. The Cas9-sgRNA complex is wrapped on the outside of UCNPs by PEI and SiO2, which have the capability to convert near-infrared light (980 nm) to ultraviolet light for the Cas9-sgRNA complex to bind to target genes. (d) CRISPR-Cas9 systems based on APC gold nanoparticles. Cas9 plasmids carrying the heat-induced promoter can be efficiently delivered into mice by APC gold nanoparticles. Under near infrared light irradiation at 1064 nm, APC gold nanoparticles can convert light energy to heat, which activates the expression of Cas9 nuclease for genome editing. (e) A far-red light-activated split-Cas9 (FAST) system. The far-red light activates the expression of the fusion proteinNCas9-Coh2, and the CMV promoter drives the expression of the fusion protein DocS-CCas9, which consequently activates Cas9 nuclease by heterodimerization between Coh2 and DocS.

Fig. 11 Light-controlled gene transcription systems based on CRISPR-dCas9(a) Photoactivable dCas9-meidated transcription systems based on CRY2-CIBN. Under dark conditions, dCas9 is splitted into two fragments without catalytic activity. With blue-light illumination, CRY2 undergoes a conformational change that enables interactions with CIBN, which causes translocation of the transactivator VP64 to activate downstream gene transcription. (b) Blue light-controlled dCas9-meidated gene transcription systems based on SAM and pMag-nMag. SAM, a synergistic activation mediator that extends guide RNAs with an insertion of a MS2-box sequence into the loop of gRNA, can recruit effector protein to initiate gene transcription. Under blue-light illumination conditions, the NdCas9 and CdCas9 domains can be reassociated to form a complete dCas9 by the light-dependent dimerization of pMag and nMag, thereby activating the downstream gene transcription. (c) A far red light-controlled gene transcription system based on SAM and BphS-BldD. Under far-red light illumination conditions, the fused protein MS2-p65-HSF1 can express to activate the target gene transcription. (d) Light-controlled dCas9-midated gene transcription systems based on REDMAP. Under red-light illumination conditions, the heterodimerization of ΔPhyA and FHY1 enables the expression of the fused protein MS2-p65-HSF1 to activate endogenous gene expression by sgRNAs-mediated recruitment of the transcriptional activator domain.

Fig. 12 Light-controlled gene transcription and editing systems based on CRISPR-Cas12a/dCas12a(a) Blue light-controlled split-Cas12a gene editing systems. Under blue-light illumination conditions, pMag and nMagHigh1 that are fused to dCas12a are reassociated by the dimerization of pMag and nMag, thereby recovering the catalytic activity of Cas12a to cleave the target DNA sequence. (b) Far-red light-controlled Cas12a gene editing systems. Under far-red light illumination conditions, BphS can convert GTP into c-di-GMP to trigger the dimerization of p65-HSF1-BldD for binding with the operator to induce the expression of Cas12a for targeted genome cleavage. (c) Far-red light-controlled gene transcription systems based on SunTag and BphS-BldD. Under far-red light illumination conditions, the expression of the fusion protein dCas12a-GCN4 can be induced to activate the target gene transcription by the recruitment of the transactivator fused with ScFv.

Fig. 13 Light-controlled transgene expression systems based on RNA level(a) Light-controlled transgene expression systems based on PAL. Under dark conditions, PAL is dissociated from the RNA aptamer to initiate reporter gene expression. With blue light illumination, PAL can bind to RNA aptamer, which can suppress the reporter gene expression. (b) Light-controlled transgene expression systems based on LicV. A stem-loop inserted termination sequence hinders the reporter gene expression, and under blue light illumination, the dimerized VVDs enables dimerization of CATs, which binds to the RAT sequence and unfold the stem-loop, thereby restoring the reporter gene expression.

Fig. 14 Light-controlled movement and localization of organelles(a) Light-controlled organelle localization based on CRY2-CIB1. Under blue-light illumination conditions, CRY2 undergoes a conformational change that enables interactions with CIBN for the movement of organelles driven by the molecular motor. (b) Light-controlled localization of organelles based on LOV. Under blue light irradiation conditions, the organelles fused with PEX-LOV can bind to the engineered PDZ domain ePDZb1fused with molecular motor, leading to the movement and localization of organelle.

Fig. 15 Optogenetic tools for intelligent bioelectronic medicine(a) A brain-controlled wireless-powered optogenetic implant device for transgene expression. This brain-controlled transgenic expression device can wirelessly control gene expression through human brain activities. Electroencephalogram (EEG) headset captures brain wave activities and transmits them to the field intensity generator interface (BCI) through Bluetooth, which integrates with a near-infrared LED. The bacterial diguanylate cyclase (DGC) can be activated by near-infrared light, which converts GTP into c-di-GMP for the activation of the STING signal pathway to initiate the transgene expression. (b) Semi-automatic intelligent diagnosis and treatment systems based on optogenetic designer cells for diabetes treatment. The blood glucose value detected from the blood glucose monitor can be automatically transmitted to the smart controller and smart phone through Bluetooth. The smart controller can regulate far-red light intensity based on the blood glucose value. Under far-red light irradiation, BphS converts intracellular GTP into c-di-GMP, which dimerizes the hybrid transcriptional activator p65-VP64-BldD into the nucleus for binding to the chimeric promoter to initiate the expression of insulin or GLP-1 for controlling blood glucose homeostasis. (c) Wearable smart watch-controlled optogenetic systems for disbetes treatment. The system utilizes green light from a smartwatch to activate artificially customized cells implanted into the skin of mice. The green light-responsive TtCBD is anchored onto the cell membrane. When the LEDs are turned on, TtCBD is depolymerized, and the hybrid transcriptional activator TetR-VPR is separated from the cell membrane to initiate the transcription expression of GLP-1for controlling blood glucose homeostasis.

References 217

1	BOYDEN E S, ZHANG F, BAMBERG E, et al. Millisecond-timescale, genetically targeted optical control of neural activity[J]. Nature Neuroscience, 2005, 8(9): 1263-1268.
2	BI A D, CUI J J, MA Y P, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration[J]. Neuron, 2006, 50(1): 23-33.
3	NEWS STAFF THE. Insights of the decade. Stepping away from the trees for a look at the forest. Introduction[J]. Science, 2010, 330(6011): 1612-1613.
4	Method of the year 2010[J]. Nature Methods, 2011, 8(1): 1.
5	FAVORY J J, STEC A, GRUBER H, et al. Interaction of COP1 and UVR8 regulates UV-B-induced photomorphogenesis and stress acclimation in Arabidopsis [J]. The EMBO Journal, 2009, 28(5): 591-601.
6	WU Y I, FREY D, LUNGU O I, et al. A genetically encoded photoactivatable Rac controls the motility of living cells[J]. Nature, 2009, 461(7260): 104-108.
7	YE H F, DAOUD-EL BABA M, PENG R W, et al. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice[J]. Science, 2011, 332(6037): 1565-1568.
8	WANG X, CHEN X J, YANG Y. Spatiotemporal control of gene expression by a light-switchable transgene system[J]. Nature Methods, 2012, 9(3): 266-269
9	KAINRATH S, STADLER M, REICHHART E, et al. Green-light-induced inactivation of receptor signaling using cobalamin-binding domains[J]. Angewandte Chemie International Edition, 2017, 56(16): 4608-4611.
10	LEVSKAYA A, WEINER O D, LIM W A, et al. Spatiotemporal control of cell signalling using a light-switchable protein interaction[J]. Nature, 2009, 461(7266): 997-1001.
11	HEYES D J, KHARA B, SAKUMA M, et al. Ultrafast red light activation of Synechocystis phytochrome Cph1 triggers major structural change to form the Pfr signalling-competent state[J]. PLoS One, 2012, 7(12): e52418.
12	KABERNIUK A A, SHEMETOV A A, VERKHUSHA V V. A bacterial phytochrome-based optogenetic system controllable with near-infrared light[J]. Nature Methods, 2016, 13(7): 591-597.
13	SHAO J W, XUE S, YU G L, et al. Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice[J]. Science Translational Medicine, 2017, 9(387): eaal2298.
14	SHAO J W, WANG M Y, YU G L, et al. Synthetic far-red light-mediated CRISPR-dCas9 device for inducing functional neuronal differentiation[J]. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115(29): E6722-E6730.
15	CHEN X H, CHEN Y X, XIN H H, et al. Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(5): 2395-2405.
16	NIHONGAKI Y, FURUHATA Y, OTABE T, et al. CRISPR-Cas9-based photoactivatable transcription systems to induce neuronal differentiation [J]. Nature methods, 2017, 14(10): 963-966.
17	POLSTEIN L R, GERSBACH C A. A light-inducible CRISPR-Cas9 system for control of endogenous gene activation[J]. Nature Chemical Biology, 2015, 11(3): 198-200.
18	YU Y H, WU X, GUAN N Z, et al. Engineering a far-red light-activated split-Cas9 system for remote-controlled genome editing of internal organs and tumors[J]. Science Advances, 2020, 6(28): eabb1777
19	NIHONGAKI Y, KAWANO F, NAKAJIMA T, et al. Photoactivatable CRISPR-Cas9 for optogenetic genome editing[J]. Nature Biotechnology, 2015, 33(7): 755-760.
20	HEMPHILL J, BORCHARDT E K, BROWN K, et al. Optical control of CRISPR/Cas9 gene editing[J]. Journal of the American Chemical Society, 2015, 137(17): 5642-5645.
21	JAIN P K, RAMANAN V, SCHEPERS A G, et al. Development of light-activated CRISPR using guide RNAs with photocleavable protectors[J]. Angewandte Chemie International Edition, 2016, 55(40): 12440-12444.
22	BUGAJ L J, CHOKSI A T, MESUDA C K, et al. Optogenetic protein clustering and signaling activation in mammalian cells[J]. Nature Methods, 2013, 10(3): 249-252.
23	WAGNER J C, PLATT R J, GOLDFLESS S J, et al. Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum [J]. Nature Methods, 2014, 11(9): 915-918.
24	TAN P, HE L, HUANG Y, et al. Optophysiology: illuminating cell physiology with optogenetics[J]. Physiological Reviews, 2022, 102(3): 1263-1325.
25	GOVORUNOVA E G, SINESHCHEKOV O A, JANZ R, et al. Natural light-gated anion channels: a family of microbial rhodopsins for advanced optogenetics[J]. Science, 2015, 349(6248): 647-650.
26	HANKINS M W, PEIRSON S N, FOSTER R G. Melanopsin: an exciting photopigment[J]. Trends in Neurosciences, 2008, 31(1): 27-36.
27	WEISSENBERGER S, SCHULTHEIS C, LIEWALD J F, et al. PACα-an optogenetic tool for in vivo manipulation of cellular cAMP levels, neurotransmitter release, and behavior in Caenorhabditis elegans [J]. Journal of Neurochemistry, 2011, 116(4): 616-625.
28	NOGLY P, STANDFUSS J. Light-driven Na⁺ pumps as next-generation inhibitory optogenetic tools[J]. Nature Structural & Molecular Biology, 2015, 22(5): 351-353.
29	GLANTZ S T, BERLEW E E, JABER Z, et al. Directly light-regulated binding of RGS-LOV photoreceptors to anionic membrane phospholipids[J]. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115(33): E7720-E7727.
30	HUANG Z L, WU Y Q, ALLEN M E, et al. Engineering light-controllable CAR T cells for cancer immunotherapy[J]. Science Advances, 2020, 6(8): eaay9209.
31	ALI A M, REIS J M, XIA Y, et al. Optogenetic inhibitor of the transcription factor CREB[J]. Chemistry & Biology, 2015, 22(11): 1531-1539.
32	RIZZINI L, FAVORY J J, CLOIX C, et al. Perception of UV-B by the Arabidopsis UVR8 protein[J]. Science, 2011, 332(6025): 103-106.
33	KIM C K, CHO K F, KIM M W, et al. Luciferase-LOV BRET enables versatile and specific transcriptional readout of cellular protein-protein interactions[J]. eLife, 2019, 8: e43826.
34	PATEL A L, YEUNG E, MCGUIRE S E, et al. Optimizing photoswitchable MEK[J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(51): 25756-25763.
35	JUNG H, KIM S W, KIM M, et al. Noninvasive optical activation of Flp recombinase for genetic manipulation in deep mouse brain regions[J]. Nature Communications, 2019, 10: 314.
36	YAO S Q, YUAN P, OUELLETTE B, et al. RecV recombinase system for in vivo targeted optogenomic modifications of single cells or cell populations[J]. Nature Methods, 2020, 17(4): 422-429.
37	ENDO M, IWAWAKI T, YOSHIMURA H, et al. Photocleavable cadherin inhibits cell-to-cell mechanotransduction by light[J]. ACS Chemical Biology, 2019, 14(10): 2206-2214.
38	ZHANG X L, DONG C M, HUANG W Y, et al. Rational design of a photo-responsive UVR8-derived protein and a self-assembling peptide-protein conjugate for responsive hydrogel formation[J]. Nanoscale, 2015, 7(40): 16666-16670.
39	CHEN D, GIBSON E S, KENNEDY M J. A light-triggered protein secretion system[J]. The Journal of Cell Biology, 2013, 201(4): 631-640.
40	REED E H, SCHUSTER B S, GOOD M C, et al. SPLIT: stable protein coacervation using a light induced transition[J]. ACS Synthetic Biology, 2020, 9(3): 500-507.
41	ZHANG W, LOHMAN A W, ZHURAVLOVA Y, et al. Optogenetic control with a photocleavable protein, PhoCl[J]. Nature Methods, 2017, 14(4): 391-394.
42	ZHANG W M, ZHAO G H, LUO Z Q, et al. Engineering the ribosomal DNA in a megabase synthetic chromosome[J]. Science, 2017, 355(6329): eaaf3981.
43	ABDO H, CALVO-ENRIQUE L, LOPEZ J M, et al. Specialized cutaneous Schwann cells initiate pain sensation[J]. Science, 2019, 365(6454): 695-699.
44	ALEXANDRE M T A, ARENTS J C, VAN GRONDELLE R, et al. A base-catalyzed mechanism for dark state recovery in the Avena sativa phototropin-1 LOV2 domain[J]. Biochemistry, 2007, 46(11): 3129-3137.
45	HEINTZEN C, LOROS J, DUNLAP J C. The PAS protein VIVID defines a clock-associated feedback loop that represses light input, modulates gating, and regulates clock resetting[J]. Cell, 2001, 104: 453-464.
46	FREDDOLINO P L, DITTRICH M, SCHULTEN K. Dynamic switching mechanisms in LOV1 and LOV2 domains of plant phototropins[J]. Biophysical Journal, 2006, 91(10): 3630-3639.
47	HARPER S M, NEIL L C, GARDNER K H. Structural basis of a phototropin light switch[J]. Science, 2003, 301(5639): 1541-1544.
48	HE L, TAN P, ZHU L, et al. Circularly permuted LOV2 as a modular photoswitch for optogenetic engineering[J]. Nature Chemical Biology, 2021, 17(8): 915-923.
49	KAWANO F, SUZUKI H, FURUYA A, et al. Engineered pairs of distinct photoswitches for optogenetic control of cellular proteins[J]. Nature Communications, 2015, 6: 6256.
50	NAGEL G, OLLIG D, FUHRMANN M, et al. Channelrhodopsin-1: a light-gated proton channel in green algae[J]. Science, 2002, 296(5577): 2395-2398.
51	NAGEL G, SZELLAS T, HUHN W, et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel[J]. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(24): 13940-13945
52	PARK H, KIM N Y, LEE S, et al. Optogenetic protein clustering through fluorescent protein tagging and extension of CRY2[J]. Nature Communications, 2017, 8: 30.
53	TASLIMI A, VRANA J D, CHEN D, et al. An optimized optogenetic clustering tool for probing protein interaction and function[J]. Nature Communications, 2014, 5: 4925.
54	KENNEDY M J, HUGHES R M, PETEYA L A, et al. Rapid blue-light-mediated induction of protein interactions in living cells[J]. Nature Methods, 2010, 7(12): 973-975.
55	MOTTA-MENA L B, READE A, MALLORY M J, et al. An optogenetic gene expression system with rapid activation and deactivation kinetics[J]. Nature Chemical Biology, 2014, 10(3): 196-202.
56	WANG R, YANG Z G, LUO J R, et al. B₁₂-dependent photoresponsive protein hydrogels for controlled stem cell/protein release[J]. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(23): 5912-5917.
57	JOST M, FERNÁNDEZ-ZAPATA J, POLANCO M C, et al. Structural basis for gene regulation by a B₁₂-dependent photoreceptor[J]. Nature, 2015, 526(7574): 536-541.
58	MANSOURI M, HUSSHERR M D, STRITTMATTER T, et al. Smart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes[J]. Nature Communications, 2021, 12: 3388.
59	XU D D, RICKEN J, WEGNER S V. Turning cell adhesions ON or OFF with high spatiotemporal precision using the green light responsive protein CarH[J]. Chemistry, 2020, 26(44): 9859-9863.
60	HABUCHI S, ANDO R, DEDECKER P, et al. Reversible single-molecule photoswitching in the GFP-like fluorescent protein Dronpa[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(27): 9511-9516.
61	DAY R N, DAVIDSON M W. The fluorescent protein palette: tools for cellular imaging[J]. Chemical Society Reviews, 2009, 38(10): 2887-2921.
62	ZHOU X X, CHUNG H K, LAM A J, et al. Optical control of protein activity by fluorescent protein domains[J]. Science, 2012, 338(6108): 810-814.
63	ZHOU X X, FAN L Z, LI P P, et al. Optical control of cell signaling by single-chain photoswitchable kinases[J]. Science, 2017, 355(6327): 836-842.
64	TOETTCHER J E, WEINER O D, LIM W A. Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module[J]. Cell, 2013, 155(6): 1422-1434.
65	OCHOA-FERNANDEZ R, SAMODELOV S L, BRANDL S M, et al. Optogenetics in plants: red/far-red light control of gene expression[J]. Methods in Molecular Biology, 2016, 1408: 125-139.
66	WU J L, WANG M Y, YANG X P, et al. A non-invasive far-red light-induced split-Cre recombinase system for controllable genome engineering in mice[J]. Nature Communications, 2020, 11: 3708.
67	YU G L, ZHANG M L, GAO L, et al. Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control[J]. Molecular Therapy, 2022, 30(1): 341-354.
68	REDCHUK T A, OMELINA E S, CHERNOV K G, et al. Near-infrared optogenetic pair for protein regulation and spectral multiplexing[J]. Nature Chemical Biology, 2017, 13(6): 633-639.
69	REDCHUK T A, KARASEV M M, VERKHUSHA P V, et al. Optogenetic regulation of endogenous proteins[J]. Nature Communications, 2020, 11: 605.
70	SOROKINA O, KAPUS A, TERECSKEI K, et al. A switchable light-input, light-output system modelled and constructed in yeast[J]. Journal of Biological Engineering, 2009, 3: 15.
71	ZHOU Y, KONG D Q, WANG X Y, et al. A small and highly sensitive red/far-red optogenetic switch for applications in mammals[J]. Nature Biotechnology, 2022, 40(2): 262-272.
72	CHRISTIE J M, ARVAI A S, BAXTER K J, et al. Plant UVR8 photoreceptor senses UV-B by tryptophan-mediated disruption of cross-dimer salt bridges[J]. Science, 2012, 335(6075): 1492-1496.
73	SARRIS M, OLEKHNOVITCH R, BOUSSO P. Manipulating leukocyte interactions in vivo through optogenetic chemokine release[J]. Blood, 2016, 127(23): e35-e41.
74	LEE J, NATARAJAN M, NASHINE V C, et al. Surface sites for engineering allosteric control in proteins[J]. Science, 2008, 322(5900): 438-442.
75	PETER E, DICK B, BAEURLE S A. Mechanism of signal transduction of the LOV2-Jα photosensor from Avena sativa [J]. Nature Communications, 2010, 1: 122.
76	LUNGU O I, HALLETT R A, CHOI E J, et al. Designing photoswitchable peptides using the AsLOV2 domain[J]. Chemistry & Biology, 2012, 19(4): 507-517.
77	HARTWICK A T E, BRAMLEY J R, YU J N, et al. Light-evoked calcium responses of isolated melanopsin-expressing retinal ganglion cells[J]. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience, 2007, 27(49): 13468-13480.
78	BAASKE J, GONSCHOREK P, ENGESSER R, et al. Dual-controlled optogenetic system for the rapid down-regulation of protein levels in mammalian cells[J]. Scientific Reports, 2018, 8: 15024.
79	VAN HAREN J, CHARAFEDDINE R A, ETTINGER A, et al. Local control of intracellular microtubule dynamics by EB1 photodissociation[J]. Nature Cell Biology, 2018, 20(3): 252-261.
80	BUBECK F, HOFFMANN M D, HARTEVELD Z, et al. Engineered anti-CRISPR proteins for optogenetic control of CRISPR-Cas9[J]. Nature Methods, 2018, 15(11): 924-927.
81	RENICKE C, SCHUSTER D, USHERENKO S, et al. A LOV2 domain-based optogenetic tool to control protein degradation and cellular function[J]. Chemistry & Biology, 2013, 20(4): 619-626.
82	GIL A A, CARRASCO-LÓPEZ C, ZHU L Y, et al. Optogenetic control of protein binding using light-switchable nanobodies[J]. Nature Communications, 2020, 11: 4044.
83	KAWANO F, OKAZAKI R, YAZAWA M, et al. A photoactivatable Cre-loxP recombination system for optogenetic genome engineering[J]. Nature Chemical Biology, 2016, 12(12): 1059-1064.
84	FOIGHT G W, WANG Z Z, WEI C T, et al. Multi-input chemical control of protein dimerization for programming graded cellular responses[J]. Nature Biotechnology, 2019, 37(10): 1209-1216.
85	VISWANATHAN R, HARTMANN J, PALLARES CARTES C, et al. Desensitisation of Notch signalling through dynamic adaptation in the nucleus[J]. The EMBO Journal, 2021, 40(18): e107245.
86	YUMEREFENDI H, WANG H, DICKINSON D J, et al. Light-dependent cytoplasmic recruitment enhances the dynamic range of a nuclear import photoswitch[J]. ChemBioChem, 2018, 19(12): 1319-1325.
87	GRIFFIN E A, STAKNIS D, WEITZ C J. Light-independent role of CRY1 and CRY2 in the mammalian circadian clock[J]. Science, 1999, 286(5440): 768-771.
88	AIRAN R D, THOMPSON K R, FENNO L E, et al. Temporally precise in vivo control of intracellular signalling[J]. Nature, 2009, 458(7241): 1025-1029.
89	ZHANG F, WANG L P, BRAUNER M, et al. Multimodal fast optical interrogation of neural circuitry[J]. Nature, 2007, 446(7136): 633-639.
90	GRADINARU V, ZHANG F, RAMAKRISHNAN C, et al. Molecular and cellular approaches for diversifying and extending optogenetics[J]. Cell, 2010, 141(1): 154-165.
91	ZHAO S L, CUNHA C, ZHANG F, et al. Improved expression of halorhodopsin for light-induced silencing of neuronal activity[J]. Brain Cell Biology, 2008, 36(1/2/3/4): 141-154.
92	HUGHES R M, BOLGER S, TAPADIA H, et al. Light-mediated control of DNA transcription in yeast[J]. Methods, 2012, 58(4): 385-391.
93	PIATKEVICH K D, SUBACH F V, VERKHUSHA V V. Engineering of bacterial phytochromes for near-infrared imaging, sensing, and light-control in mammals[J]. Chemical Society Reviews, 2013, 42(8): 3441-3452.
94	TSCHOWRI N, SCHUMACHER M A, SCHLIMPERT S, et al. Tetrameric c-di-GMP mediates effective transcription factor dimerization to control Streptomyces development[J]. Cell, 2014, 158(5): 1136-1147.
95	BUSH M J, TSCHOWRI N, SCHLIMPERT S, et al. C-di-GMP signalling and the regulation of developmental transitions in streptomycetes[J]. Nature Reviews Microbiology, 2015, 13(12): 749-760.
96	RYU M H, GOMELSKY M. Near-infrared light responsive synthetic c-di-GMP module for optogenetic applications[J]. ACS Synthetic Biology, 2014, 3(11): 802-810.
97	ASH C, DUBEC M, DONNE K, et al. Effect of wavelength and beam width on penetration in light-tissue interaction using computational methods[J]. Lasers in Medical Science, 2017, 32(8): 1909-1918.
98	CRICK F H. Thinking about the brain[J]. Scientific American, 1979, 241(3): 219-232.
99	DEISSEROTH K, FENG G P, MAJEWSKA A K, et al. Next-generation optical technologies for illuminating genetically targeted brain circuits[J]. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience, 2006, 26(41): 10380-10386.
100	ADAMANTIDIS A R, ZHANG F, DE LECEA L, et al. Optogenetics: opsins and optical interfaces in neuroscience[J]. Cold Spring Harbor Protocols, 2014, 2014(8): 815-822.
101	BURN D J, TRÖSTER A I. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease[J]. Journal of Geriatric Psychiatry and Neurology, 2004, 17(3): 172-180.
102	LIU A L, VÖRÖSLAKOS M, KRONBERG G, et al. Immediate neurophysiological effects of transcranial electrical stimulation[J]. Nature Communications, 2018, 9: 5092.
103	ZEMELMAN B V, LEE G A, NG M, et al. Selective photostimulation of genetically ChARGed neurons[J]. Neuron, 2002, 33(1): 15-22.
104	BANGHART M, BORGES K, ISACOFF E, et al. Light-activated ion channels for remote control of neuronal firing[J]. Nature Neuroscience, 2004, 7(12): 1381-1386.
105	LIMA S Q, MIESENBöCK G. Remote control of behavior through genetically targeted photostimulation of neurons[J]. Cell, 2005, 121(1): 141-152.
106	SCHROLL C, RIEMENSPERGER T, BUCHER D, et al. Light-induced activation of distinct modulatory neurons triggers appetitive or aversive learning in Drosophila larvae[J]. Current Biology, 2006, 16(17): 1741-1747.
107	JUNG J C, MEHTA A D, AKSAY E, et al. In vivo mammalian brain imaging using one- and two-photon fluorescence microendoscopy[J]. Journal of Neurophysiology, 2004, 92(5): 3121-3133.
108	HELMCHEN F, FEE M S, TANK D W, et al. A miniature head-mounted two-photon microscope: high-resolution brain imaging in freely moving animals[J]. Neuron, 2001, 31(6): 903-912.
109	HAN X, BOYDEN E S. Multiple-color optical activation, silencing, and desynchronization of neural activity, with single-spike temporal resolution[J]. PLoS One, 2007, 2(3): e299.
110	MU D, DENG J, LIU K F, et al. A central neural circuit for itch sensation[J]. Science, 2017, 357(6352): 695-699.
111	GRADINARU V, MOGRI M, THOMPSON K R, et al. Optical deconstruction of parkinsonian neural circuitry[J]. Science, 2009, 324(5925): 354-359.
112	NGUGI A K, BOTTOMLEY C, KLEINSCHMIDT I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach[J]. Epilepsia, 2010, 51(5): 883-890.
113	TØNNESEN J, SØRENSEN A T, DEISSEROTH K, et al. Optogenetic control of epileptiform activity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(29): 12162-12167.
114	HE L, WANG L Q, ZENG H X, et al. Engineering of a bona fide light-operated calcium channel[J]. Nature Communications, 2021, 12: 164.
115	GONG X, MENDOZA-HALLIDAY D, TING J T, et al. An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques[J]. Neuron, 2020, 107(1): 38-51.e8.
116	CHEN R, GORE F, NGUYEN Q A, et al. Deep brain optogenetics without intracranial surgery[J]. Nature Biotechnology, 2021, 39(2): 161-164.
117	KIM C K, SANCHEZ M I, HOERBELT P, et al. A molecular calcium integrator reveals a striatal cell type driving aversion[J]. Cell, 2020, 183(7): 2003-2019.e16.
118	TAN P, HONG T T, CAI X L, et al. Optical control of protein delivery and partitioning in the nucleolus[J]. Nucleic Acids Research, 2022, 50(12): e69.
119	STANCULEANU D L, DANIELA Z, LAZESCU A, et al. Development of new immunotherapy treatments in different cancer types[J]. Journal of Medicine and Life, 2016, 9(3): 240-248.
120	LIZÉE G, OVERWIJK W W, RADVANYI L, et al. Harnessing the power of the immune system to target cancer[J]. Annual Review of Medicine, 2013, 64: 71-90.
121	RESTIFO N P, DUDLEY M E, ROSENBERG S A. Adoptive immunotherapy for cancer: harnessing the T cell response[J]. Nature Reviews Immunology, 2012, 12(4): 269-281.
122	KHADER S A, DIVANGAHI M, HANEKOM W, et al. Targeting innate immunity for tuberculosis vaccination[J]. The Journal of Clinical Investigation, 2019, 129(9): 3482-3491.
123	FISHER B, PACKARD B S, READ E J, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 1989, 7(2): 250-261.
124	GRIFFITH K D, READ E J, CARRASQUILLO J A, et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma[J]. Journal of the National Cancer Institute, 1989, 81(22): 1709-1717.
125	FRIDMAN W H, PAGÈS F, SAUTÈS-FRIDMAN C, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nature Reviews Cancer, 2012, 12(4): 298-306.
126	TAN P, HE L, HAN G, et al. Optogenetic immunomodulation: shedding light on antitumor immunity[J]. Trends in Biotechnology, 2017, 35(3): 215-226.
127	XU Y X, HYUN Y M, LIM K, et al. Optogenetic control of chemokine receptor signal and T-cell migration[J]. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(17): 6371-6376.
128	HE L, ZHANG Y W, MA G L, et al. Near-infrared photoactivatable control of Ca²⁺ signaling and optogenetic immunomodulation[J]. eLife, 2015, 4: e10024.
129	ZHAO B X, WANG Y C, TAN X H, et al. An optogenetic controllable T cell system for hepatocellular carcinoma immunotherapy[J]. Theranostics, 2019, 9(7): 1837-1850.
130	ZHENG B, WANG H J, PAN H Z, et al. Near-infrared light triggered upconversion optogenetic nanosystem for cancer therapy[J]. ACS Nano, 2017, 11(12): 11898-11907.
131	KALIKI S, SHIELDS C L. Uveal melanoma: relatively rare but deadly cancer[J]. Eye, 2017, 31(2): 241-257.
132	AMARO A, GANGEMI R, PIAGGIO F, et al. The biology of uveal melanoma[J]. Cancer Metastasis Reviews, 2017, 36(1): 109-140.
133	SHAIN A H, BAGGER M M, YU R, et al. The genetic evolution of metastatic uveal melanoma[J]. Nature Genetics, 2019, 51(7): 1123-1130.
134	ZHANG M L, LIN X, ZHANG J P, et al. Blue light-triggered optogenetic system for treating uveal melanoma[J]. Oncogene, 2020, 39(10): 2118-2124.
135	HE L, HUANG Z X, HUANG K, et al. Optogenetic control of non-apoptotic cell death[J]. Advanced Science, 2021, 8(13): 2100424.
136	JACOBY E, NGUYEN S M, FOUNTAINE T J, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity[J]. Nature Communications, 2016, 7: 12320.
137	MAUS M V, JUNE C H. Making better chimeric antigen receptors for adoptive T-cell therapy[J]. Clinical Cancer Research, 2016, 22(8): 1875-1884.
138	FRIGAULT M J, LEE J, BASIL M C, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells[J]. Cancer Immunology Research, 2015, 3(4): 356-367.
139	TOKAREW N, OGONEK J, ENDRES S, et al. Teaching an old dog new tricks: next-generation CAR T cells[J]. British Journal of Cancer, 2019, 120(1): 26-37.
140	CALIENDO F, DUKHINOVA M, SICILIANO V. Engineered cell-based therapeutics: synthetic biology meets immunology[J]. Frontiers in Bioengineering and Biotechnology, 2019, 7: 43.
141	CRUZ C R, HANLEY P J, LIU H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience[J]. Cytotherapy, 2010, 12(6): 743-749.
142	NGUYEN N T, HUANG K, ZENG H X, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety[J]. Nature Nanotechnology, 2021, 16(12): 1424-1434.
143	ZHOU S B, GRAVEKAMP C, BERMUDES D, et al. Tumour-targeting bacteria engineered to fight cancer[J]. Nature Reviews Cancer, 2018, 18(12): 727-743.
144	ZHANG X Y, ZHANG Y Y, ZHANG C N, et al. An injectable hydrogel co-loading with cyanobacteria and upconversion nanoparticles for enhanced photodynamic tumor therapy[J]. Colloids and Surfaces B: Biointerfaces, 2021, 201: 111640.
145	PAN H Z, LI L Y, PANG G J, et al. Engineered NIR light-responsive bacteria as anti-tumor agent for targeted and precise cancer therapy[J]. Chemical Engineering Journal, 2021, 426: 130842.
146	FLORES-MATEO G, CARRILLO-SANTISTEVE P, ELOSUA R, et al. Antioxidant enzyme activity and coronary heart disease: meta-analyses of observational studies[J]. American Journal of Epidemiology, 2009, 170(2): 135-147
147	MOZAFFARIAN D, BENJAMIN E J, GO A S, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association[J]. Circulation, 2015, 131(4): e29-e322.
148	PRIORI S G, BLOMSTRÖM-LUNDQVIST C, MAZZANTI A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)[J]. European Heart Journal, 2015, 36(41): 2793-2867.
149	COHEN J E, PURCELL B P, MACARTHUR J W, et al. A bioengineered hydrogel system enables targeted and sustained intramyocardial delivery of neuregulin, activating the cardiomyocyte cell cycle and enhancing ventricular function in a murine model of ischemic cardiomyopathy[J]. Circulation Heart Failure, 2014, 7(4): 619-626.
150	ASCHEIM D D, GELIJNS A C, GOLDSTEIN D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices[J]. Circulation, 2014, 129(22): 2287-2296.
151	YANKEY G K, LI T L, KILIC A, et al. Regional remodeling strain and its association with myocardial apoptosis after myocardial infarction in an ovine model[J]. The Journal of Thoracic and Cardiovascular Surgery, 2008, 135(5): 991-998.e2.
152	VELAZQUEZ E J, LEE K L, DEJA M A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J]. The New England Journal of Medicine, 2011, 364(17): 1607-1616.
153	COHEN J E, GOLDSTONE A B, PAULSEN M J, et al. An innovative biologic system for photon-powered myocardium in the ischemic heart[J]. Science Advances, 2017, 3(6): e1603078.
154	AMBROSI C M, BOYLE P M, CHEN K, et al. Optogenetics-enabled assessment of viral gene and cell therapy for restoration of cardiac excitability[J]. Scientific Reports, 2015, 5: 17350.
155	KOLOSSOV E, BOSTANI T, ROELL W, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium[J]. The Journal of Experimental Medicine, 2006, 203(10): 2315-2327.
156	BRUEGMANN T, MALAN D, HESSE M, et al. Optogenetic control of heart muscle in vitro and in vivo [J]. Nature Methods, 2010, 7(11): 897-900.
157	NUSSINOVITCH U, GEPSTEIN L. Optogenetics for in vivo cardiac pacing and resynchronization therapies[J]. Nature Biotechnology, 2015, 33(7): 750-754.
158	YU L L, , ZHOU L P, CAO G, et al. Optogenetic modulation of cardiac sympathetic nerve activity to prevent ventricular arrhythmias[J]. Journal of the American College of Cardiology, 2017, 70(22): 2778-2790.
159	TILLEY D G. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function[J]. Circulation Research, 2011, 109(2): 217-230.
160	KOCKSKÄMPER J, ZIMA A V, RODERICK H L, et al. Emerging roles of inositol 1, 4, 5-trisphosphate signaling in cardiac myocytes[J]. Journal of Molecular and Cellular Cardiology, 2008, 45(2): 128-147.
161	BEIERT T, BRUEGMANN T, SASSE P. Optogenetic activation of Gq signalling modulates pacemaker activity of cardiomyocytes[J]. Cardiovascular Research, 2014, 102(3): 507-516.
162	BOJAR D, SCHELLER L, HAMRI G C E, et al. Caffeine-inducible gene switches controlling experimental diabetes[J]. Nature Communications, 2018, 9: 2318.
163	XIE M Q, YE H F, WANG H, et al. β-Cell-mimetic designer cells provide closed-loop glycemic control[J]. Science, 2016, 354(6317): 1296-1301.
164	LI T, CHEN X J, QIAN Y J, et al. A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice[J]. Nature Communications, 2021, 12: 615.
165	REINBOTHE T M, SAFI F, AXELSSON A S, et al. Optogenetic control of insulin secretion in intact pancreatic islets with β-cell-specific expression of Channelrhodopsin-2[J]. Islets, 2014, 6(1): e28095.
166	KUSHIBIKI T, OKAWA S, HIRASAWA T, et al. Optogenetic control of insulin secretion by pancreatic β-cells in vitro and in vivo [J]. Gene Therapy, 2015, 22(7): 553-559.
167	BELKAID Y, HAND T W. Role of the microbiota in immunity and inflammation[J]. Cell, 2014, 157(1): 121-141.
168	DURACK J, LYNCH S V. The gut microbiome: relationships with disease and opportunities for therapy[J]. The Journal of Experimental Medicine, 2019, 216(1): 20-40.
169	ZHU W H, WINTER M G, BYNDLOSS M X, et al. Precision editing of the gut microbiota ameliorates colitis[J]. Nature, 2018, 553(7687): 208-211.
170	CUI M H, SUN T, LI S, et al. NIR light-responsive bacteria with live bio-glue coatings for precise colonization in the gut[J]. Cell Reports, 2021, 36(11): 109690.
171	CUI M H, PANG G J, ZHANG T, et al. Optotheranostic nanosystem with phone visual diagnosis and optogenetic microbial therapy for ulcerative colitis at-home care[J]. ACS Nano, 2021, 15(4): 7040-7052.
172	PAN H Z, SUN T, CUI M H, et al. Light-sensitive lactococcus lactis for microbe-gut-brain axis regulating via upconversion optogenetic micro-nano system[J]. ACS Nano, 2022, 16(4): 6049-6063.
173	COMMITTEE ON SCIENCE T, LAW, POLICY, et al. The National Academies Collection: Reports funded by National Institutes of Health [M]. //OLSON S. International Summit on Human Gene Editing: A Global Discussion. Washington (DC): National Academies Press, 2016.
174	NAGY A. Cre recombinase: the universal reagent for genome tailoring[J]. Genesis, 2000, 26(2): 99-109.
175	DOW L E, FISHER J, O'ROURKE K P, et al. Inducible in vivo genome editing with CRISPR-Cas9[J]. Nature Biotechnology, 2015, 33(4): 390-394.
176	ZETSCHE B, VOLZ S E, ZHANG F. A split-Cas9 architecture for inducible genome editing and transcription modulation[J]. Nature Biotechnology, 2015, 33(2): 139-142.
177	DAVIS K M, PATTANAYAK V, THOMPSON D B, et al. Small molecule-triggered Cas9 protein with improved genome-editing specificity[J]. Nature Chemical Biology, 2015, 11(5): 316-318.
178	NGUYEN D P, MIYAOKA Y, GILBERT L A, et al. Ligand-binding domains of nuclear receptors facilitate tight control of split CRISPR activity[J]. Nature Communications, 2016, 7: 12009.
179	PAN Y C, YANG J J, LUAN X W, et al. Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform[J]. Science Advances, 2019, 5(4): eaav7199.
180	GILBERT L A, LARSON M H, MORSUT L, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes[J]. Cell, 2013, 154(2): 442-451.
181	QI L S, LARSON M H, GILBERT L A, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression[J]. Cell, 2013, 152(5): 1173-1183.
182	NIHONGAKI Y, YAMAMOTO S, KAWANO F, et al. CRISPR-cas9-based photoactivatable transcription system[J]. Chemistry & Biology, 2015, 22(2): 169-174.
183	ZETSCHE B, GOOTENBERG J S, ABUDAYYEH O O, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system[J]. Cell, 2015, 163(3): 759-771.
184	KLEINSTIVER B P, SOUSA A A, WALTON R T, et al. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing[J]. Nature Biotechnology, 2019, 37(3): 276-282.
185	KIM D, KIM J, HUR J K, et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells[J]. Nature Biotechnology, 2016, 34(8): 863-868.
186	KLEINSTIVER B P, TSAI S Q, PREW M S, et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells[J]. Nature Biotechnology, 2016, 34(8): 869-874.
187	NIHONGAKI Y, OTABE T, UEDA Y, et al. A split CRISPR-Cpf1 platform for inducible genome editing and gene activation[J]. Nature Chemical Biology, 2019, 15(9): 882-888.
188	WANG X Y, DONG K L, KONG D Q, et al. A far-red light-inducible CRISPR-Cas12a platform for remote-controlled genome editing and gene activation[J]. Science Advances, 2021, 7(50): eabh2358.
189	WEBER A M, KAISER J, ZIEGLER T, et al. A blue light receptor that mediates RNA binding and translational regulation[J]. Nature Chemical Biology, 2019, 15(11): 1085-1092.
190	PILSL S, MORGAN C, CHOUKEIFE M, et al. Optoribogenetic control of regulatory RNA molecules[J]. Nature Communications, 2020, 11: 4825.
191	LIU R M, YANG J, YAO J, et al. Optogenetic control of RNA function and metabolism using engineered light-switchable RNA-binding proteins[J]. Nature Biotechnology, 2022, 40(5): 779-786.
192	VALE R D. The molecular motor toolbox for intracellular transport[J]. Cell, 2003, 112(4): 467-480.
193	WILLIAMSON R E. Organelle movements along actin filaments and microtubules[J]. Plant Physiology, 1986, 82(3): 631-634.
194	PERICO C, SPARKES I. Plant organelle dynamics: cytoskeletal control and membrane contact sites[J]. New Phytologist, 2018, 220(2): 381-394.
195	BAAS P W, DEITCH J S, BLACK M M, et al. Polarity orientation of microtubules in hippocampal neurons: uniformity in the axon and nonuniformity in the dendrite[J]. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85(21): 8335-8339.
196	CONDE C, CÁCERES A. Microtubule assembly, organization and dynamics in axons and dendrites[J]. Nature Reviews Neuroscience, 2009, 10(5): 319-332.
197	DUAN L T, CHE D, ZHANG K, et al. Optogenetic control of molecular motors and organelle distributions in cells[J]. Chemistry & Biology, 2015, 22(5): 671-682.
198	VAN BERGEIJK P, ADRIAN M, HOOGENRAAD C C, et al. Optogenetic control of organelle transport and positioning[J]. Nature, 2015, 518(7537): 111-114.
199	FISCHBACH M A, BLUESTONE J A, LIM W A. Cell-based therapeutics: the next pillar of medicine[J]. Science Translational Medicine, 2013, 5(179): 179ps7.
200	FOLCHER M, OESTERLE S, ZWICKY K, et al. Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant[J]. Nature Communications, 2014, 5: 5392.
201	JENAL U, MALONE J. Mechanisms of cyclic-di-GMP signaling in bacteria[J]. Annual Review of Genetics, 2006, 40: 385-407.
202	BURDETTE D L, MONROE K M, SOTELO-TROHA K, et al. STING is a direct innate immune sensor of cyclic di-GMP[J]. Nature, 2011, 478(7370): 515-518.
203	GOMELSKY M. Photoactivated cells link diagnosis and therapy[J]. Science Translational Medicine, 2017, 9(387): eaan3936.
204	MICKLE A D, WON S M, NOH K N, et al. A wireless closed-loop system for optogenetic peripheral neuromodulation[J]. Nature, 2019, 565(7739): 361-365.
205	KATHE C, MICHOUD F, SCHÖNLE P, et al. Wireless closed-loop optogenetics across the entire dorsoventral spinal cord in mice[J]. Nature Biotechnology, 2022, 40(2): 198-208.
206	BATABYAL T, BRODOVSKAYA A, WILLIAMSON J, et al. A deep learning-based automated closed-loop optogenetic system for neuromodulation during seizures[EB/OL]. bioRxiv (2022-04-21)[2022-05-01]. .
207	TANG J, DU Y P, LEE C A, et al. Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro [J]. Investigative Ophthalmology & Visual Science, 2013, 54(5): 3681-3690.
208	ZHANG F, TZANAKAKIS E S. Amelioration of diabetes in a murine model upon transplantation of pancreatic β-cells with optogenetic control of cyclic adenosine monophosphate[J]. ACS Synthetic Biology, 2019, 8(10): 2248-2255.
209	XIE M Q, YE H F, HAMRI G C E, et al. Antagonistic control of a dual-input mammalian gene switch by food additives[J]. Nucleic Acids Research, 2014, 42(14): e116.
210	GITZINGER M, KEMMER C, FLURI D A, et al. The food additive vanillic acid controls transgene expression in mammalian cells and mice[J]. Nucleic Acids Research, 2011, 40(5): e37.
211	CHEN R, ROMERO G, CHRISTIANSEN M G, et al. Wireless magnetothermal deep brain stimulation[J]. Science, 2015, 347(6229): 1477-1480.
212	HERNÁNDEZ-MORALES M, SHANG T, CHEN J J, et al. Lipid oxidation induced by RF waves and mediated by ferritin iron causes activation of ferritin-tagged ion channels[J]. Cell Reports, 2020, 30(10): 3250-3260.e7.
213	DECKERS R, QUESSON B, ARSAUT J, et al. Image-guided, noninvasive, spatiotemporal control of gene expression[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(4): 1175-1180.
214	PAN Y J, YOON S, SUN J, et al. Mechanogenetics for the remote and non-invasive control of cancer immunotherapy[J]. The FASEB Journal, 2018, 32: 674.24.
215	SHKARINA K, HASEL DE CARVALHO E, SANTOS J C, et al. Optogenetic activators of apoptosis, necroptosis, and pyroptosis[J]. The Journal of Cell Biology, 2022, 221(6): e202109038.
216	YIZHAR O, FENNO L E, DAVIDSON T J, et al. Optogenetics in neural systems[J]. Neuron, 2011, 71(1): 9-34
217	OWEN S F, LIU M H, KREITZER A C. Thermal constraints on in vivo optogenetic manipulations[J]. Nature Neuroscience, 2019, 22(7): 1061-1065.

[1]	Zhidian DIAO, Xixian WANG, Qing SUN, Jian XU, Bo MA. Advances and applications of single-cell Raman spectroscopy testing and sorting equipment [J]. Synthetic Biology Journal, 2023, 4(5): 1020-1035.
[2]	Hui LU, Fangli ZHANG, Lei HUANG. Establishment of iBioFoundry for synthetic biology applications [J]. Synthetic Biology Journal, 2023, 4(5): 877-891.
[3]	Zhonghu BAI, He REN, Jianqi NIE, Yang SUN. The recent progresses and applications of in-parallel fermentation technology [J]. Synthetic Biology Journal, 2023, 4(5): 904-915.
[4]	Yujie WU, Xinxin LIU, Jianhui LIU, Kaiguang Yang, Zhigang SUI, Lihua ZHANG, Yukui ZHANG. Research progress of strain screening and quantitative analysis of key molecules based on high-throughput liquid chromatography and mass spectrometry [J]. Synthetic Biology Journal, 2023, 4(5): 1000-1019.
[5]	Zhehui HU, Juan XU, Guangkai BIAN. Application of automated high-throughput technology in natural product biosynthesis [J]. Synthetic Biology Journal, 2023, 4(5): 932-946.
[6]	Huan LIU, Qiu CUI. Advances and applications of ambient ionization mass spectrometry in screening of microbial strains [J]. Synthetic Biology Journal, 2023, 4(5): 980-999.
[7]	Yannan WANG, Yuhui SUN. Base editing technology and its application in microbial synthetic biology [J]. Synthetic Biology Journal, 2023, 4(4): 720-737.
[8]	Wanqiu LIU, Xiangyang JI, Huiling XU, Yicong LU, Jian LI. Cell-free protein synthesis system enables rapid and efficient biosynthesis of restriction endonucleases [J]. Synthetic Biology Journal, 2023, 4(4): 840-851.
[9]	Meili SUN, Kaifeng WANG, Ran LU, Xiaojun JI. Rewiring and application of Yarrowia lipolytica chassis cell [J]. Synthetic Biology Journal, 2023, 4(4): 779-807.
[10]	Zhi SUN, Ning YANG, Chunbo LOU, Chao TANG, Xiaojing YANG. Rational design for functional topology and its applications in synthetic biology [J]. Synthetic Biology Journal, 2023, 4(3): 444-463.
[11]	Qilong LAI, Shuai YAO, Yuguo ZHA, Hong BAI, Kang NING. Microbiome-based biosynthetic gene cluster data mining techniques and application potentials [J]. Synthetic Biology Journal, 2023, 4(3): 611-627.
[12]	Qiaozhen MENG, Fei GUO. Applications of foldability in intelligent enzyme engineering and design: take AlphaFold2 for example [J]. Synthetic Biology Journal, 2023, 4(3): 571-589.
[13]	Sheng WANG, Zechen WANG, Weihua CHEN, Ke CHEN, Xiangda PENG, Fafen OU, Liangzhen ZHENG, Jinyuan SUN, Tao SHEN, Guoping ZHAO. Design of synthetic biology components based on artificial intelligence and computational biology [J]. Synthetic Biology Journal, 2023, 4(3): 422-443.
[14]	Hailong LV, Jian WANG, Hao LV, Jin WANG, Yong XU, Dayong GU. Synthetic biology for next-generation genetic diagnostics [J]. Synthetic Biology Journal, 2023, 4(2): 318-332.
[15]	Zhaoling SHEN, Yanling WU, Tianlei YING. Synthetic biology and viral vaccine development [J]. Synthetic Biology Journal, 2023, 4(2): 333-346.

Advances in optogenetics for biomedical research

光遗传学照进生物医学研究进展

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 16

References 217

Related Articles 15

Recommended Articles

Metrics

Comments